Month: December 2012

Effects of Light Exposure, pH, Osmolarity, and Solvent on the Retinal Pigment Epithelial Toxicity of Vital Dyes

Purpose: To investigate the in vitro effect of pH, osmolarity, solvent, and light interaction on currently used and novel dyes to minimize dye-related retinal toxicity.Design: Laboratory investigation.Methods: Retinal pigment epithelium (RPE) human cells (ARPE-19) were exposed for 10 minutes to different pH solutions (4, 5, 6, 7, 7.5, 8, and 9) and glucose solutions (2.5%, 5.0%, 10%, 20%, 40%, and 50%) with osmolarity from 142 to 2530 mOsm, with and without 0.5 mg/mL trypan blue. R28 cells were also incubated with glucose (150, 310, and 1000 mOsm) and mannitol used as an osmotic control agent in both experiments. Dye-light interaction was assessed by (Read more...)

Combined Depth Imaging Technique on Spectral-Domain Optical Coherence Tomography

Purpose: To describe a technique to obtain combined images of vitreoretinal and choroidal structures using spectral-domain (SD) optical coherence tomography (OCT) and to evaluate applicability in normal eyes and limitations in eyes with cataract.Design: Prospective, observational case series.Methods: Three different foveal scans, including conventional SD OCT, enhanced depth imaging OCT and the novel method called combined depth imaging (CDI) OCT, were obtained in 42 eyes of healthy volunteers and in 26 eyes with cataract using the Heidelberg Spectralis HRA (Heidelberg Engineering). The CDI OCT images were obtained manually using an image modification process that enhances the vitreoretinal interface first and (Read more...)

Change to injection needle supplied with ranibizumab (Lucentis®)

Source: Personal communication (Novartis)
Area: News
Novartis Pharmaceuticals UK Limited is advising customers of a forthcoming change to the injection needle supplied in packs of ranibizumab (Lucentis®). 
 
The needle supplier is being switched from Becton & Dickinson to B.Braun at the end of December 2012. Customers may therefore notice a difference in the appearance of the injection needle and the outer packaging of the needle. Novartis has stressed that the rest of the pack will remain the same, including the filter needle.